Jul 30, 2019
Progentec Diagnostics and Karate Health Announce Merger to Further Develop Comprehensive Autoimmune Disease Management Platforms
Jul 25, 2019
Progentec Diagnostics Awarded SBIR Fast-Track Grant to Develop Immune Mediator-Based Blood Tests for Clinical Disease Activity in Lupus (SLE)
Jul 09, 2019
Virginia Based AMPEL BioSolutions' Machine Learning Breakthrough Predicts Chronic Disease Flares From A Blood Sample
Jun 13, 2019
VALUE Study Results Show Custom Mobile App Lets Patients Accurately Report Response to Treatment
Jun 13, 2019
First-in-Human Data Presented from Phase 1a Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology
Jun 10, 2019
Rheumatoid Arthritis - Can its Onset be Delayed or Prevented
May 30, 2019
Immunic, Inc. to Participate in Investor and Scientific Conferences in June
May 29, 2019
New Study Partly Funded by the Lupus Research Alliance Reveals Novel Lupus Drug Targets
May 20, 2019
Lupus Treatments Can Be Tailored to Patient's Individual Cells, Study Shows
May 14, 2019
IMMUNE 3D® Expands Platform into New Disease Areas and Enters into Drug Discovery
May 13, 2019
IQuity Research Unveils Potential $18 Billion in Health Plan Cost-Savings and Demonstrates Effectiveness of Identifying At-Risk Autoimmune Disease Patients
May 08, 2019
Kyle Marcelli Wins AARDA Champion Award for his Drive to Eradicate Autoimmune Diseases
May 01, 2019
Lupus Research Alliance Kicks Off Lupus Awareness Month with "Breaking through for Lupus Research: 20 Years of Progress"
Apr 26, 2019
Bone Abnormalities in Systemic Autoimmune Disease
Apr 23, 2019
Mallinckrodt Lupus Phase 4 Clinical Study for Acthar® Gel (Repository Corticotropin Injection) Completes Enrollment in Difficult-to-Manage Population
Apr 15, 2019
Hansa Biopharma Receives Ethics and Regulatory Clearance to Start Phase 2 Study of Imlifidase in Guillain Barré Syndrome
Apr 01, 2019
Novartis to Acquire IFM Tre to Develop First-In-Class NLRP3 Antagonist Portfolio Targeting Innate Immune System
Mar 28, 2019
Provention Bio Appoints Jeffrey Bluestone, PhD, to Board of Directors
Mar 20, 2019
Cyxone Announces Strategic Intent to Position its Drug Candidate T20K in MS as a Prophylactic Agent
Mar 06, 2019
Reducing B Cells with Modified CAR T Cells is an Effective Treatment of Experimental Lupus